@Replicate_Bio profile picture
Replicate Bioscience, Inc. @Replicate_Bio
Joined June 2020
  • Tweets 71
  • Following 34
  • Followers 122
Photos and videos
What makes srRNA different? Once inside your cells, it doesn’t just deliver an instruction, it delivers the machinery to keep copying it. Thank you to @cure345 for spotlighting Replicate among the companies shaping the future of mRNA vaccines. wewillcure.com/insights/comp…

8 Biotech Companies Driving Breakthroughs in mRNA Vaccines

From self-amplifying RNA to programmable, cell-selective therapies, a new class of biotech companies is pushing mRNA beyond vaccines and into precision medicine across cancer, rare disease, and...

wewillcure.com
23
Proud to be named one of @FastCompany's 2026 Most Innovative Companies. From rabies, to RSV combination vaccines, to obesity - our srRNA platform is changing what’s possible in medicine at a fraction of the dose. Read more about this year’s winners: fastcompany.com/most-innovat…
29
Malaria and HIV remain urgent global health challenges. We are honored to partner with the @gatesfoundation to advance new srRNA vaccine candidates designed specifically for impact in low- and middle-income countries. Read more: replicatebioscience.com/repl…
0:16
30
We are thrilled to appoint Kathy Fernando, Ph.D., as CBO. With nearly 20 years of experience, including leadership roles at Pfizer & Deloitte, she joins to help accelerate our pipeline and bring #srRNA therapies to patients worldwide. Read more: replicatebioscience.com/repl…
28
Today we announced the publication of our Phase 1 trial for RBI-4000, our #srRNA rabies vaccine, in @CommsMedicine. Results show durability 6x greater than standard vaccines - a first for #RNA. Learn more: nature.com/articles/s43856-0…

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open...

Communications Medicine - Maine et al., report post-hoc modeling of a secondary outcome of a Phase 1 clinical trial that assessed the long-term immunogenicity of a next-generation self-replicating...

nature.com
1
2
130
We’re kicking off September at #RNALeaders USA Congress – where CEO Nathaniel Wang will speak to the advantages of srRNA, including durability. We look forward to discussing Replicate’s latest progress, as well as the advantages of srRNA - we hope to see you there!
66
Big news today: Replicate enters a $550M exclusive deal with @novonordisk Together, we’ll advance our self-replicating RNA (srRNA) technology for obesity, type 2 diabetes, and cardiometabolic disease. A milestone moment for RNA therapeutics. Read more: replicatebioscience.com/repl…

Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA...

Partnership leverages Replicate’s proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research...

replicatebioscience.com
5
163
Today we announced a paper in @NatureComms highlighting our Phase I clinical study of RBI-4000 an #srRNA rabies #vaccine. Results suggest RBI-4000 could offer much needed treatment option for #rabies. Congratulations to all who contributed to this work! nature.com/articles/s41467-0…

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose...

Nature Communications - Here the authors report an optimized self-replicating RNA (srRNA) vaccine approach that generates protective immunity at much lower doses than mRNA vaccines in mice. In a...

nature.com
4
4
274
Replicate CEO Nathaniel Wang and CBO Rachael Lester will be at the @Piper_Sandler 36th Annual Healthcare Conference held December 3-5 in NYC. Reach out to schedule 1:1s and hear more about our latest company updates - we hope to see you there! #srRNA #biotech #mRNA #RNA #vaccine
103
Don’t miss our presentation today at the 12th International #mRNA Health Conference. Our Head of R&D, Parinaz (Paris) Aliahmad, will share data from our rabies clinical trial showing the expanded therapeutic index of a novel, optimized #srRNA #vaccine. #Biotech #RNA
75
On November 14th, our CBO Rachael Lester will participate in a roundtable hosted by @FT focused on funding biopharma innovation to discuss asset development and corporate growth in a complex and evolving macroeconomic environment. #Biotech #BusinessDevelopment #Industry
45
Mark your calendar: Next week, our Head of Research & Development, Parinaz (Paris) Aliahmad, will present clinical data demonstrating the expanded therapeutic index of a novel #srRNA #vaccine at the 12th International #mRNA Health Conference. We hope to see you there!
1
52
Next week, Replicate will attend the DCVMN International 25th Annual General Meeting. We look forward to insightful discussions on prioritizing accessibility in #vaccine development, manufacturing, and roll out to ensure that scientific advancements benefit all populations. #RNA
2
67
Our CBO Rachael Lester will be in NYC next week to present at the Oppenheimer Private Healthcare Company Showcase. Reach out to schedule meetings and learn how we’re expanding the utility of #RNAtherapeutics with our next generation #srRNA vectors. #biotech #mRNA #vaccine
58
San Diego is a true hub of scientific innovation and a premier location for #RNATherapeutics R&D! @CONNECTinSD 3rd Annual Innovation Day, our CDO and Co-founder Andrew Geall will showcase the positive impact of #RNA medicines on public health. #srRNA #Biotech #SanDiego #IDSD24
1
34
Join our CEO Nathaniel Wang and CBO Rachael Lester for a fireside chat at the @MorganStanley 22nd Annual Global Healthcare Conference on September 6th. We look forward to engaging discussions and collaborations that shape the future of #RNATherapies! #RNA #srRNA #mRNA #vaccine
51
Come see us in San Diego for the #RNALeaders USA Congress! Today, our CEO @nathanielswang will discuss scaling strategies for #RNAtherapies during a keynote panel before presenting on key improvements enabled by our #srRNA technology in the afternoon. #mRNA #RNA #vaccine
1
238
We’re looking forward to engaging with the #biotech and #pharma partnering community next week in San Diego at #BIO2024! convention.bio.org/
1
52
If you’re attending, our CEO Nathaniel Wang and CBO Rachael Lester will be onsite to discuss Replicate’s progress and the partnership opportunities using Replicate’s groundbreaking srRNA platform for vaccines and therapeutic proteins. We hope to see you there!
33
Join Andy Geall onsite at #TIDESUSA, where he is moderating a panel highlighting the next chapter of mRNA-based medicines and the broad utility of the field in addressing current hurdles in infectious disease and other therapeutic areas.
1
58
Load more